Results 131 to 140 of about 137,616 (341)

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability‐enhancing strategies

British Journal of Clinical Pharmacology, EarlyView.
Aims The study aims to predict and improve the absorption of tyrosine kinase inhibitors (TKIs) in patients with malabsorption issues, particularly those who have undergone bariatric surgery or are using proton‐pump inhibitors. The research involves 2 main components: the development of an artificial intelligence (AI) model to identify TKIs that are ...
Daan W. Huntjens, Olivier J. M. Béquignon, Stefanie D. Krens, Mark Löwenberg, Martine E. D. Chamuleau, Remco J. Molenaar, Anita M. G. Kramers, Marianne A. Kuijvenhoven, Imke H. Bartelink   +8 more
wiley   +1 more source

Lactobacillus rhamnosus GG ameliorates triptolide-induced liver injury through modulation of the bile acid-FXR axis

Pharmacological Research
Triptolide (TP) is the principal bioactive compound of Tripterygium wilfordii with significant anti-tumor, anti-inflammatory and immunosuppressive activities. However, its severe hepatotoxicity greatly limits its clinical use. The underlying mechanism of
Shiping Hu, Bo Tang, Cheng Lu, Sumin Wang, Lingyi Wu, Yuanyuan Lei, Li Tang, Hongbin Zhu, Dongxu Wang, Shiming Yang   +9 more
doaj   +1 more source

The protective effect of nicotinamide on carbon tetrachloride-induced hepatotoxicity [PDF]

, 1967
James W. Gibb, Thomas Brody
openalex   +1 more source

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

British Journal of Clinical Pharmacology, EarlyView.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo, Juan Eduardo Resendiz‐Galvan, Letisha Najjemba, Henry Mugerwa, Amedeo De Nicolò, Antonio D'Avolio, Shakir Atoyebi, Lubbe Wiesner, Elin M. Svensson, Catriona Waitt, Paolo Denti   +10 more
wiley   +1 more source

SOME ASPECTS OF EXPERIMENTAL CARBON TETRA‐CHLORIDE‐INDUCED HEPATOTOXICITY* [PDF]

, 1963
Theodore M. Brody
openalex   +1 more source

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Anete Šperberga, Marisa D. Muckian, James W. Dear, Liga Kuksa, Derek J. Sloan, Helen R. Stagg   +10 more
wiley   +1 more source

ABCG2 polymorphisms and susceptibility to ARV‐associated hepatotoxicity

Molecular Genetics & Genomic Medicine
Background The ABCG2 421C/A polymorphism contributes significantly to the distribution and absorption of antiretroviral (ARV) regimens and is associated with the undesirable side effects of efavirenz. Methods To investigate this, we examined ABCG2 34G/A (
HariOm Singh, Kishore Dhotre, Shyamveer, Ranjana Choudhari, Amita Verma, Supriya D. Mahajan, Nemat Ali   +6 more
doaj   +1 more source

Halothane hepatotoxicity [PDF]

, 1965
M.J. KIRWAN, J. W. Dundee, R.S.J. CLARKE, Ellen Siobhan Mitchell, D. W. Neill   +4 more
openalex   +1 more source

Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure

British Journal of Clinical Pharmacology, EarlyView.
Fexuprazan, a potassium‐competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We report a case of idiosyncratic drug‐induced liver injury in a 61‐year‐old woman following 2 months of fexuprazan therapy.
Sook Jin Seong, O Seong Kweon, Young‐Ran Yoon, Yu Kyung Kim, Yoo Na Kang, Se Young Jang   +5 more
wiley   +1 more source